Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human umbilical cord mesenchymal stem cell (hUC-MSC) exosomes are extracellular vesicles derived from hUC-MSCs that contain a cargo of bioactive molecules, including proteins, lipids, and various RNA species (such as miRNAs). Developed by the Sixth Affiliated Hospital, Sun Yat-sen University, these exosomes are being investigated as a cell-free regenerative therapy for intrauterine adhesions (IUA) and thin endometrium. The therapeutic approach involves intrauterine perfusion of the exosomes following hysteroscopic surgery to promote endometrial repair. The mechanism of action is believed to involve paracrine signaling that modulates the local uterine environment, stimulates endometrial cell proliferation, enhances angiogenesis, and reduces subendometrial fibrosis. This modality aims to restore uterine cavity morphology and improve endometrial receptivity for embryo implantation, offering a potentially safer and more standardized alternative to direct stem cell transplantation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human umbilical cord mesenchymal stem cell exosomes (Sixth Affiliated Hospital, Sun Yat-sen University).